Pulsed radiofrequency treatment reduces chronic knee pain by blocking the release of inflammatory neuropeptides CGRP and substance P through impaired nerve signaling.
Complete reversal with peptide agonistsCGRP and substance P agonists completely nullified PRF's pain relief, proving these neuropeptides are the essential mechanism
What the researchers found
PRF applied to the sciatic nerve significantly reduced knee pain, synovitis, and inflammatory cytokines in a mouse model. Tracer studies and western blotting showed PRF inhibited axonal transport in small dorsal root ganglion neurons, suppressing secretion of CGRP and substance P into the knee joint. Critically, administering CGRP and substance P agonists completely reversed PRF's analgesic and anti-inflammatory effects, proving these neuropeptides are the essential mediators of PRF's therapeutic action.
Why it matters
CGRP and substance P are major neuropeptides involved in pain and inflammation — CGRP is already the target of breakthrough migraine drugs. Understanding that PRF works specifically by suppressing these peptides could help optimize the treatment for different pain conditions and may reveal new therapeutic approaches targeting these neuropeptide pathways.
How the study worked
Researchers used a monoiodoacetic acid-induced knee pain model in mice. PRF was applied to the sciatic nerve and its effects were assessed through pain behavior testing, synovitis scoring, inflammatory cytokine measurements, tracer studies to evaluate axonal transport, and western blotting of dorsal root ganglion neurons. Reversal experiments with CGRP and substance P agonists confirmed the causal mechanism.
What this study cannot tell us
This is a mouse study using a chemically induced pain model, which may not fully represent human chronic pain conditions. The monoiodoacetic acid model specifically mimics osteoarthritis-type pain, limiting generalizability to other chronic pain types. Specific sample sizes and statistical values were not detailed in the abstract. Translation to human PRF treatment parameters would require clinical validation.
How to read the evidence
This is a preclinical animal study (mouse model) with well-designed mechanistic experiments including reversal studies. While the mechanism is convincingly demonstrated in mice, human clinical confirmation is still needed.
When this study was published
Published in 2025, this is very recent research that provides a mechanistic explanation for a treatment already in clinical use, making it immediately relevant to understanding current pain management practices.
The bigger picture
This study connects two important areas: physical neuromodulation techniques (like PRF) and neuropeptide biology. As CGRP-targeting drugs revolutionize migraine treatment and substance P research advances pain medicine, understanding how existing treatments interact with these peptide systems helps build a more complete picture of pain management.
Questions still open
- Could monitoring CGRP and substance P levels serve as biomarkers to predict or confirm PRF treatment success in humans?
- Would combining PRF with CGRP-targeting drugs (like those used for migraines) produce synergistic pain relief?
- Does this mechanism explain why PRF works better for some pain conditions than others?
Common questions
What are CGRP and substance P, and why do they matter for pain?
What is pulsed radiofrequency and how does it treat pain?
Read the original research
Elucidation of the treatment mechanism of pulsed radiofrequency based on its antiinflammatory effects.
Scientific reports, 15(1), 33611
Citation
Yuba, Tomoo; Koyama, Yoshihisa; Uematsu, Hironobu; Takahashi, Ayako; Matsuda, Yoichi; Fujino, Yuji; Shimada, Shoichi. (2025). Elucidation of the treatment mechanism of pulsed radiofrequency based on its antiinflammatory effects.. Scientific reports, 15(1), 33611. https://doi.org/10.1038/s41598-025-19045-z